EGFR and metastatic neoplasm: Our article reviews the strategy of combining anti-angiogenic therapy with chemotherapy and immunotherapy for NSCLC patients with de novo metastatic disease and those patients with EGFR-mutated NSCLC who have failed previous TKI, and it explores the possibility of using this regimen for patients with stage III unresectable disease and those with brain metastases.